广州市241例新型冠状病毒肺炎患者的抗病毒治疗用药分析  

Analysis of antiviral therapy in 241 cases with Corona Virus Disease 2019 in Guangzhou

作　　者：张婧[1] 周波[1] 汪明 简凤璧[1] 周花萍 梁蓉蓉 应若素[2] 谭俊[1] ZHANG Jing;ZHOU Bo;WANG Ming;JIAN Fengbi;ZHOU Huaping;LIANG Rongrong;YING Ruosu;TAN Jun(Department of Pharmacy,Guangzhou Eighth People’s Hospital,Guangzhou 510060,China;Therapeutic Center for Infectious Disease,Guangzhou Eighth People’s Hospital,Guangzhou 510060,China)

机构地区：[1]广州市第八人民医院药剂科,广东广州510060 [2]广州市第八人民医院感染病治疗中心,广东广州510060

出　　处：《暨南大学学报（自然科学与医学版）》2020年第4期358-365,共8页Journal of Jinan University(Natural Science & Medicine Edition)

基　　金：广州市卫生健康科技项目(20191A011039)。

摘　　要：目的:掌握新型冠状病毒肺炎(新冠肺炎)的抗病毒治疗用药现状,并探讨其中的药学监护点,为促进临床合理用药和提升药学服务提供参考.方法:采用回顾性分析,对新冠肺炎定点收治医院广州市第八人民医院2020年1月26日至3月12日出院的新冠肺炎患者的抗病毒治疗用药、药物疗效及安全性进行考察,并探讨其中的药学监护点.结果:共有241例患者采用抗病毒治疗,占同期新冠肺炎患者的80.60%,治愈出院比例94.19%.初始治疗以洛匹那韦/利托那韦、阿比多尔和磷酸氯喹单药治疗为主,29.88%的患者需进行治疗方案调整.本研究期间,洛匹那韦/利托那韦治疗比例逐渐下降,阿比多尔和磷酸氯喹用药比例先后上升.共71例(29.46%)患者出现了抗病毒药物相关的不良反应.结论:新冠肺炎的临床治疗以抗病毒单药治疗为主,常用药物为洛匹那韦/利托那韦、阿比多尔和磷酸氯喹,后两种药物在临床治疗中逐渐被优选.用药过程中需注意监测胃肠道反应、心电图和肝肾功能等,避免不良的药物相互作用.同时,应加强重型及危重型患者的个体化治疗和药学监护.Objective:To master the situation of antiviral treatment for Corona Virus Disease 2019(COVID-19),and explore the key points of pharmaceutical care,providing a reference for promoting clinical rational administration of drug and pharmaceutical care for COVID-19 patients.Methods:Retrospective analysis method was adopted to analyze the antiviral treatment,clinical efficacy and safety for COVID-19 outpatients from Jan/26,2020 to Mar/12,2020 in Guangzhou Eighth People’s Hospital,a designated hospital for COVID-19,and the key points of pharmaceutical care was investigated.Results:A total of 241 patients received antiviral treatment,accounting for 80.60%of COVID-19 patients discharged in the same period,the rate of cure was 94.19%.The initial treatment was single drug therapy of lopinavir/ritonavir,arbidol and chloroquine phosphate,29.88%of the patients needed to adjust the treatment plan.During the study period,the proportion of treatment with lopinavir/ritonavir decreased gradually,and the proportion of arbidol and chloroquine phosphate increased successively.And 71 patients(29.46%)had antiviral drug-related ADRs.Conclusion:The clinical treatment of COVID-19 was mainly antiviral monotherapy.The commonly used drugs were lopinavir/ritonavir,arbidol and chloroquine phosphate,the latter two drugs were gradually optimized in clinical treatment.It was necessary to monitor the gastrointestinal reaction,electrocardiogram,liver and kidney function during the treatment,and avoid adverse DDIs.Meanwhile,the individual treatment and pharmaceutical care for severe and critical patients should be strengthened.

关 键 词：新型冠状病毒肺炎(新冠肺炎) 抗病毒治疗 用药分析 药学监护 

分 类 号：R978.7[医药卫生—药品]